In the management of PNETs it is important to differentiate between functional and nonfunctional PNETs in order to determine the course of treatment.
Overall survival significantly longer for patients with actionable molecular alterations receiving matched therapy.
Results of this study showed no improvement in the rate of 30-day hospital readmission for patients with cancer undergoing pancreatectomy between 2005 and 2011.
Promising results from an earlier-phase study of FOLFOX plus pegilodecakin in metastatic PDAC refractory to gemcitabine provided a rationale for this study.
Pegvorhyaluronidase alfa is an enzyme that breaks down hyaluronan, thought to be a contributor to the structure of the tumor microenvironment in some pancreatic cancers.